Management of early aggressive rheumatoid arthritis during pregnancy and lactation

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 9, 2009, Pages 1469-1479

  Østensen, Monika ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Early rheumatoid arthritis; Lactation; Pregnancy; Therapy

Indexed keywords

ABATACEPT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

BREAST FEEDING; CROHN DISEASE; DRUG CONTRAINDICATION; HUMAN; LACTATION; PREGNANCY; PREGNANT WOMAN; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING; ULCERATIVE COLITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT; EARLY DIAGNOSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; TIME FACTORS;

EID: 67650690830     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902980194     Document Type: Review

References (99)

1. Puolakka K, Kautiainen H, Möttönen T, et al. and FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: Five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41
2. Clowse MEB, Magder LS, Witter F, et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-521 (Pubitemid 40216315)
3. Landewé RB, Boers M, Verhoven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-356 (Pubitemid 34136571)
4. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-681 (Pubitemid 38296553)
5. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-876 (Pubitemid 46768126)
6. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in early weeks of pregnancy. Teratology 1993;47:533-539 (Pubitemid 23172495)
7. Schröder H, Fogh K. Methotrexate and its polyglutamate derivates in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1988;21:145-149 (Pubitemid 18087030)
8. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998;57:51-55 (Pubitemid 28176912)
9. Østensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000;27:1872-1875
10. Kozlowski RD, Steinbrunner JV, MacKenzie AH, etal. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-592 (Pubitemid 20192270)
11. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997;40:971-973 (Pubitemid 27200016)
12. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcome. J Rheumatol 2003;30:241-246 (Pubitemid 36152584)
13. Lewden B, Vial T, Elefant E, etal. Low dose weekly methotrexate in the first trimester of pregnancy: Results of a French collaborative study. J Rheumatol 2004;31:2360-2365 (Pubitemid 39603082)
14. Østensen M, von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 2007;34:1266-1269
15. Rustin GJS, Booth M, Dent J, et al. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J 1984;288:103-106 (Pubitemid 14119397)
16. De Santis M, Straface G, Cavaliere A et al. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 2005;64:1096-1097 (Pubitemid 40909537)
17. Chambers CD, Johnson DL, Macaraeg GR, Jones KL. Pregnancy outcome following early gestational exposure to leflunomide: the OTIS Rheumatoid arthritis in pregnancy study (abstract). Pharmacoepidemiol Drug Saf 2004;13:S252
18. Scarrazini L. Pregnancy exposure to leflunomide. Postmarketing data. Presented at the advisory board meeting: Arava and pregnancy, November 29-30th, 2007, Paris
19. Neville CE, McNally J. Maternal exposure to leflunomide associated with blindness and cerebral palsy (letter). Rheumatology 2007;46:1506 (Pubitemid 47317104)
20. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008;2008:271363 (Pubitemid 352000427)
21. Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001;19:3439-3440 (Pubitemid 32642199)
22. Decker M, Rothermundt C, Holländer G, et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 2006;7:693-694 (Pubitemid 44123581)
23. Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006;91:1426-1427 (Pubitemid 44569825)
24. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Europ J Haematol 2004;72:292-295 (Pubitemid 38406563)
25. Scully M, Starke R, Lee R, etal. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006;17:459-463
26. Ojeda-Uribe M, Gilliot C, Jung G, et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006;26:252-255
27. Scott JR. Fetal growth retardation associated with maternal administration of immunosuppressives. Am J Obstet Gynecol 1977;128:668-676 (Pubitemid 8151265)
28. Reinisch JM, Simon NG. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978;202:436-438 (Pubitemid 9051835)
29. Østensen M, Fuhrer L, Mathieu R, et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004;63:1212-1217
30. de Man YA, Dolhain RJ, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;(59):1241-1248
31. Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies; a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318-1323
32. Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007;197:585e1-585e7 (Pubitemid 350166247)
33. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998;58:2-5 (Pubitemid 28404243)
34. Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Pal Craniofacial J 2003;40:624-628 (Pubitemid 37429691)
35. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92 • Well conducted cohort study and comprehensive meta-analysis.
36. Costedoat-Chalumeau N, Amoura Z, Aymard G, etal. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002;46:1123-1124
37. Hart CN, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 1964;80:407-412
38. Levy M, Buskila D, Gladman DD, et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991;8:174-178
39. Buchanan NMM, Toubi E, Khamashta KE, et al. Hydoxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996;55:486-488 (Pubitemid 26249027)
40. Costedoat-Chalumeau N, Amoura Z, Duhaut P, etal. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-11 • Detailed analysis of infant outcome after prenatal exposure to hydroxychloroquine.
41. Clowse MEB, Magder L, Witter F, Petri M. Hydoxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-3647
42. Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001;(358):813-814 (Pubitemid 32868737)
43. Norgard B, Czeizel AE, Rockenbauer M, et al. Population based case control study of the safety of sulphasalazine used during pregnancy. Aliment Pharmacol Ther 2001;15:483-486 (Pubitemid 32242773)
44. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterol 1981;80:72-76 (Pubitemid 11213291)
45. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980;21:469-474
46. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1993;18:735-742
47. Norgard B, Pedersen L, Christensen LA, Sörensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: A Danish nationwide cohort study. Am J Gastroenterol 2007;102:1406-1413 (Pubitemid 46976292)
48. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14 • Well conducted case-control study analysing the risk of birth defects caused by folic acid antagonists.
49. Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorect Dis 1997;12:220-224 (Pubitemid 27344514)
50. Bokström H, Holst RM, Hafström O, et al. Fetal haemolytic anemia associated with maternal sulfasalazine therapy during pregnancy. Acta Obstet Gynaecol Scand 2006;85:118-121 (Pubitemid 43879134)
51. Levi S, Libermann M, Levi AJ, et al. Reversible congenital neutropenia associated with maternal sulphasalazine therapy (letter). Eur J Pediat 1988;148:174-175 (Pubitemid 18276118)
52. Polifka JE, Friedman JM. Teratogen update: Azathioprine and 6-Mercaptopurine. Teratology 2002;65:240-261
53. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth def Res (Part A) 2007;79:696-701 •• A prospective,and well conducted controlled study.
54. Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985;92:233-239 (Pubitemid 15146698)
55. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. In: Cecka and Terasaki, Editors. Clin Trans 2004;103-114
56. Lamarque V, Leleu MF, Monka C, Krupp P. Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplant Proc 1997;29:2480 (Pubitemid 27373797)
57. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after CsA therapy during pregnancy: a meta-analysis. Transplantation 2001;71:1051-5 •• Detailed analysis of pregnancy outcome after exposure to ciclosporin.
58. Shaheen FAM, AI-Sulaiman MH, AI-Khader AA. Long-term nephrotoxicity after exposure to CsA in utero. Transplantation 1993;56:224-225 (Pubitemid 23220606)
59. Vasiliauskas EA, Church JA, Silverman N, et al. Evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-1258 (Pubitemid 44512222)
60. Mahadevan U, Terdiman JP, Church J, et al. Infliximab levels in infants born to women with inflammatory bowel disease. Dig Dis Week 2007;Abstract 959
61. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving Infliximab for the treatment of Crohn's Disease and Rheumatoid Arthritis. Am J Gastroenterol 2004;99:2385-92 • Largest pregnancy experience of infliximab derived from postmarketing survey.
62. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-{alpha} therapy. Rheumatology 2006;46:695-698
63. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54:890
64. Johnson DL, Jones KL Chambers CD. Pregnancy outcome in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project.Ann Rheum Dis 2008;67 (Suppl II): 303
65. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-738 (Pubitemid 40469001)
66. Hyrich K, Symmons D, Watson K, Silman A. Pregnancy outcome in women who were exposed to anti-TNF agents: results from a national population register. Arthritis Rheum 2006;54:2701-2702 (Pubitemid 44205032)
67. Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006;8:215 • Excellent overview and suggestion for prospective drug studies in pregnant patients.
68. Carter JD, Valeriano J, Vasey FB, et al. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship? J Rheumatol 2006;33:1014-1017
69. Carter JD, Ladhani A, Ricca L, et al. A safety assessment of TNF Antagonists during pregnancy: a review of the FDA database. J Rheumatol 2008,doi:10.3899/jrheum.080545
70. Østensen M. Are TNF inhibitors safe in pregnancy? Nature Rev Rheumatol 2009;5:184-185
71. Ofori B, Oraichi D, Blais L, etal. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-279
72. Cleves MA, Savell VH Jr, Raj S, et al. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2004;70:107-113 (Pubitemid 38524587)
73. Kozer E, Shekoufeh N, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. Am J Obstet Gynecol 2002;187:1623-30 • A well conducted meta-analysis.
74. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton(MA): Littleton Publishing Sciences Group, 1977;286-295
75. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 6th edition. Lippincott Williams&Wilkins: Philadelphia, 2002
76. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J 2001;322:266-270 (Pubitemid 32178552)
77. Momma K, Takeuchi H. Constriction of the ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins 1983;26:631-643 (Pubitemid 14207805)
78. Paladini D, Marasini M, Volpe P. Severe ductal constriction in the third-trimester fetus following maternal self-medication with nimesulide. Ultrasound Obstet Gynecol 2005;25:357-361 (Pubitemid 40547177)
79. Stika CS, Gross GA, Leguizamon G, et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol 2002;187:653-660
80. Alano MA, Ngougmna E, Ostrea EM, Jr KONDURI. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-523 (Pubitemid 32183186)
81. Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989;160:1525-1531 (Pubitemid 19171163)
82. van der Heijden B, Gubler MC. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1995;9:675
83. Nelson JL, Østensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:195-212
84. Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994;37:808-813
85. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate in human milk. Am J Obstet Gynecol 1972;112:978-980
86. Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993;53:324-328 (Pubitemid 23094375)
87. Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr 1985;106:1008-1011
88. Østensen M, Motta M. Review on antirheumatic drugs that can safely be used during nursing. Nature Clin Practice Rheumatol 2007;3:400-406
89. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005;25:86-89 (Pubitemid 40277379)
90. Jarnerot G, Into-Malberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol 1979;14:869-871
91. Gardiner SJ, Gearry RB, Roberst RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006;62:453-6 • A well conducted study with robust results.
92. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008;28:1209-1213
93. Nyberg G, Haljamae U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplantation 1998;(65):253-255
94. Moretti ME, Sgro M, Johnson DW, et al. Cyclosporine excretion into breast milk. Transplantation 2003;(75):2144-2146
95. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008;14:3085-3087
96. Østensen M, Eigenmann GO. Etanercept in breast milk (Letter). J Rheumatol 2004;31:1017
97. Østensen M, Khamashta M, Lockshin M, et al. Antirheumatic drugs and reproduction. Arthritis Res Ther 2006;8:209 • A consensus paper by an international group of specialists.
98. Motta M, Tincani A, Meroni PL, Cimaz R. Follow-up of children exposed ante-natally to immunosuppressive drugs. Rheumatology (Oxford) 2008;47 Suppl 3:iii32-4 • An excellent overview over an important issue.
99. Biggioggero M, Borghi MO, Gerosa M, et al. Immune function in children born to mothers with autoimmune diseases and exposed /in utero to immunosuppressants. Lupus 2007;16:651-656 (Pubitemid 47360003)